Advertisement


Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement



Nov
30
Today In Oncology
Inotuzumab Ozogamicin–Based Induction in Older Patients With Philadelphia Chromosome–Negative B-Cell–Precursor ALL
Novel AI Model May Predict Nonsmokers at High Risk for Lung Cancer
Ultraprocessed Food May Heighten Risk of Head and Neck Cancer and Esophageal Adenocarcinoma
Trastuzumab Plus Gemcitabine/Cisplatin in Advanced HER2-Positive Biliary Tract Adenocarcinoma
Incidence of Breast Cancer After False-Positive Mammography
View More 
Advertisement
© 2023 HSP News Service, L.L.C.
Designed by Harborside